Stay updated with breaking news from Andrew Bellinger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 -- Verve...
Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.
Early results of the researcher’s path-breaking gene editing treatment to permanently reduce cholesterol and prevent heart attacks have been mixed
The US company had a turnover of $10.7 million in 2022.
In a trial of 10 people with familial hypercholesterolemia, a genetic medicine reduced levels of LDL cholesterol in the blood by up to 55 percent.